SCTX (Scribe Therapeutics) Debt-to-Equity: -0.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
6 GF Score
Price $25.45
! 2 Warning Signs
View Full Analysis

What is Scribe Therapeutics Debt-to-Equity?

Scribe Therapeutics SCTX +6.89% 6 Debt-to-Equity is -0.29 as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 970 Biotechnology companies, Scribe Therapeutics ranks worse than 103092.68% on this metric.

Scribe Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $41.87 Mil. Scribe Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $4.46 Mil. Scribe Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-158.74 Mil. Scribe Therapeutics's debt to equity for the quarter that ended in Mar. 2026 was -0.29.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Scribe Therapeutics's Debt-to-Equity or its related term are showing as below:

SCTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.33   Med: -0.29   Max: -0.29
Current: -0.29

During the past 2 years, the highest Debt-to-Equity Ratio of Scribe Therapeutics was -0.29. The lowest was -0.33. And the median was -0.29.

SCTX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs SCTX: -0.29

Scribe Therapeutics  (NAS:SCTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Scribe Therapeutics Debt-to-Equity Related Terms

Scribe Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics Debt-to-Equity Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
Debt-to-Equity
-0.33 -0.29

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Debt-to-Equity -0.33 N/A -0.29 -0.29

SCTX vs : Debt-to-Equity Comparison

For the Biotechnology subindustry, Scribe Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scribe Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scribe Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Scribe Therapeutics's Debt-to-Equity falls into.


SCTX
6GF Score
Scribe Therapeutics Inc SCTX
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Scribe Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(36.624 + 4.804) / -143.419
=-0.29

Scribe Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(41.873 + 4.459) / -158.738
=-0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.29 mean?
Scribe Therapeutics (SCTX) has a Debt-to-Equity of -0.29 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scribe Therapeutics and its competitors. According to the industry distribution chart, Scribe Therapeutics ranks #999999 out of 970 companies in the Biotechnology industry.
Is Scribe Therapeutics' Debt-to-Equity too high?
Scribe Therapeutics' current Debt-to-Equity is -0.29. Based on the distribution chart, Scribe Therapeutics ranks #999999 out of 970 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scribe Therapeutics has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' Debt-to-Equity compare to ?
According to the Biotechnology industry distribution chart, Scribe Therapeutics ranks #999999 out of 970 companies for Debt-to-Equity. This places Scribe Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scribe Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scribe Therapeutics's current Debt-to-Equity is -0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current Debt-to-Equity of -0.29. The current Debt-to-Equity is -0.29. Scribe Therapeutics' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current Debt-to-Equity is -0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
6GF Score

Get the complete analysis for SCTX

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.45
Price